If you or a loved one has experienced a vaccine injury:You may be eligible for compensation through the CICP or VICP federal programs. Learn about your options →
Factual, non-partisan coverage of court rulings, federal program developments, policy changes, and peer-reviewed research relevant to mRNA countermeasure injury compensation. All reporting is sourced from public records and official government publications.
Featured Story
A Southern District of New York judge has allowed a myocarditis claim against a major vaccine manufacturer to proceed past the pleading stage, marking a significant procedural development in PREP Act immunity litigation. The ruling may have broad implications for the hundreds of similar cases currently pending in federal courts.
Why This Matters
This ruling represents one of the first instances of a federal court allowing an mRNA vaccine injury claim to survive a motion to dismiss on PREP Act grounds. Legal observers are watching closely as it may signal a shift in how courts interpret the scope of manufacturer immunity under the PREP Act.
The Health Resources & Services Administration has disclosed that CICP administrative claims reached an all-time quarterly high in Q1 2026, with cardiac injury categories representing the largest share of new filings.
A three-judge panel of the Ninth Circuit Court of Appeals heard oral arguments in three consolidated appeals challenging the breadth of PREP Act immunity for mRNA vaccine manufacturers. Attorneys for plaintiffs argued the statute was not intended to bar all state tort claims.
A large-scale epidemiological study published in a major cardiology journal has provided updated incidence estimates for myocarditis following mRNA vaccination, stratified by age, sex, and dose number. The findings are being cited in multiple pending federal litigations.
The Office of Special Masters in the U.S. Court of Federal Claims has issued updated procedural guidance clarifying the evidentiary standards that will apply to mRNA vaccine injury petitions under the Vaccine Injury Compensation Program.
Members of the House Energy and Commerce Committee questioned HRSA officials about the growing backlog of unresolved CICP claims and the adequacy of compensation amounts relative to documented injury severity.
The presiding judge in the multi-district litigation consolidating over 1,200 mRNA vaccine injury claims has issued a comprehensive case management order establishing discovery deadlines, expert witness procedures, and bellwether trial selection criteria.
The Department of Health and Human Services has published a proposed rule that would modify the administrative procedures for submitting and adjudicating CICP claims, including new documentation requirements for medical evidence.
An independent analysis of publicly available CICP filing data identifies neurological injury categories as among the most contested in terms of causation, with claimants facing significant evidentiary burdens in establishing vaccine-related causation.
The Third Circuit Court of Appeals has affirmed the dismissal of a vaccine injury civil claim on PREP Act immunity grounds, deepening an emerging circuit split that legal observers say may require Supreme Court resolution.
The annual VICP data report for fiscal year 2025 shows a significant increase in mRNA vaccine-related petitions compared to prior years, with cardiac injury categories representing a growing proportion of compensated claims.
A federal district court has denied class certification in a proposed nationwide class action alleging mRNA vaccine injuries, finding that individual causation issues predominate over common questions of law and fact.
Editorial Standards: All articles published on this platform are based exclusively on publicly available information including court records, federal agency publications, congressional records, and peer-reviewed research. This platform does not editorialize, advocate for any legal position, or represent any party in litigation. Content is provided for informational reference only.
